Program
idelalisib
Also written as “Idelalisib”, “CAL-101” and “CAL101”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Idiopathic Pulmonary Fibrosis · Primary Myelofibrosis · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 260 open or running | phase 4since Apr 12, 2016 | Jul 1, 2008 | none ahead |
| Calluna Pharma AS | 11 open or running | phase 2since Dec 16, 2024 | Dec 16, 2024 | Nov 2026phase 2 · NCT06736990 |
| Eli Lilly | 11 open or running | phase 4since Oct 16, 2025 | Oct 16, 2025 | May 2030phase 4 · NCT07218341 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Jul 1, 2008.
- Nov 14, 20122 phase 3 studies in Lymphoma, FollicularGilead Sciences · NCT01732926, NCT01732913
- Feb 19, 2013Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT01796470 · 66 enrolled · United States
- Nov 5, 20132 phase 3 studies in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT01980888, NCT01980875
- Jan 22, 2014Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02044822 · 102 enrolled · United States, Australia, Austria and more
- Sep 13, 2014Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02242045 · 6 enrolled · Japan
- Oct 3, 2014Phase 2 study in Lymphoma, FollicularGilead Sciences · NCT02258529 · 10 enrolled · United States
- May 1, 2015Phase 1 study in Primary MyelofibrosisGilead Sciences · NCT02436135 · 10 enrolled · United States
- Jun 8, 2015Phase 1 study in RecurrenceGilead Sciences · NCT02468557 · 16 enrolled · United States
- Aug 27, 2015Phase 3 study in Lymphoma, FollicularGilead Sciences · NCT02536300 · 96 enrolled · Australia, Canada, Czechia and more
- Apr 12, 2016Phase 4 study in Lymphoid MalignanciesGilead Sciences · NCT02739360 · 3 enrolled · Netherlands
- Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02968563 · 35 enrolled · Germany
- Nov 17, 2017Phase 1 study in Lymphoma, Large B-Cell, DiffuseGilead Sciences · NCT03349346 · France, Italy, Poland and more
- Dec 16, 2024Calluna Pharma AS's first study: phase 2 study in Idiopathic Pulmonary FibrosisNew to Calluna Pharma ASCalluna Pharma AS · NCT06736990 · 150 enrolled · United States, Denmark, France and more
- Oct 16, 2025Eli Lilly's first study: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Eli LillyEli Lilly · NCT07218341 · 150 planned · United States, Australia, Austria and more
Ahead
- Nov 2026Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisCalluna Pharma AS · NCT06736990
- May 2030Primary completion: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT07218341
TargetBeta
“An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) ”NCIt, by rule
“PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| duvelisibrule | SecuraBio | phase 3 | 26 |
| leniolisibrule | Pharming Group | phase 3 | 9 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| roginolisibrule | ionctura | phase 2 | 4 |
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 4 | Recruiting | Eli Lilly | May 2030 | 150 |
| NCT06736990Idiopathic Pulmonary Fibrosis · United States, Denmark, France and more | 2 | Active, not recruiting | Calluna Pharma AS | Nov 2026 | 150 |
| NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more | 1 | Withdrawn | Gilead Sciences | Feb 2021 | 0 |
| NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany | 2 | Completed | Gilead Sciences | Jun 17, 2019 | 35 |
| NCT02739360Lymphoid Malignancies · Netherlands | 4 | Terminated | Gilead Sciences | Dec 28, 2017 | 3 |
| NCT02536300Lymphoma, Follicular · Australia, Canada, Czechia and more | 3 | Terminated | Gilead Sciences | Sep 27, 2022 | 96 |
| NCT02468557Recurrence · United States | 1 | Terminated | Gilead Sciences | Apr 27, 2016 | 16 |
| NCT02436135Primary Myelofibrosis · United States | 1 | Terminated | Gilead Sciences | Nov 20, 2017 | 10 |
| NCT02258529Lymphoma, Follicular · United States | 2 | Terminated | Gilead Sciences | Apr 12, 2016 | 10 |
| NCT02242045Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 1 | Completed | Gilead Sciences | Dec 25, 2014 | 6 |
| NCT02044822Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Terminated | Gilead Sciences | Apr 27, 2016 | 102 |
| NCT01980888Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Terminated | Gilead Sciences | May 30, 2016 | 311 |
| NCT01980875Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Terminated | Gilead Sciences | May 13, 2016 | 57 |
| NCT01796470Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | Gilead Sciences | Jan 2015 | 66 |
| NCT01732926Lymphoma, Follicular · United States, Australia, Canada and more | 3 | Terminated | Gilead Sciences | May 17, 2016 | 475 |
| NCT01732913Lymphoma, Follicular · United States, Australia, Czechia and more | 3 | Terminated | Gilead Sciences | May 18, 2016 | 295 |
| NCT01659047Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | Gilead Sciences | Dec 2014 | 0 |
| NCT01659021Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Terminated | Gilead Sciences | Aug 15, 2018 | 261 |
| NCT01569295Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | Jun 10, 2019 | 416 |
| NCT01539512Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Oct 2013 | 220 |
| NCT01539291Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more | 3 | Terminated | Gilead Sciences | May 21, 2018 | 161 |
| NCT01393106Hodgkin Disease · United States | 2 | Completed | Gilead Sciences | Aug 2014 | 25 |
| NCT01306643Lymphoma, Follicular · United States | 2 | Completed | Gilead Sciences | Aug 2015 | 18 |
| NCT01282424Lymphoma, Follicular · United States, France, Germany and more | 2 | Completed | Gilead Sciences | May 2, 2018 | 125 |
| NCT01203930Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | Gilead Sciences | Aug 2015 | 105 |
| NCT01090414Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | Gilead Sciences | Jun 18, 2018 | 202 |
| NCT00836914Rhinitis, Allergic · Austria | 1 | Completed | Gilead Sciences | Mar 2009 | 41 |
| NCT00710528Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Completed | Gilead Sciences | Dec 2011 | 192 |
How it is read
Names in the registry
- “Idelalisib”, 24 entries
- “CAL-101”, 2 entries
- “CAL101”, 1 entry
- “GS-1101”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 15 studies
- Lymphoma, Follicular, 6 studies
- Idiopathic Pulmonary Fibrosis, 1 study
- Primary Myelofibrosis, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.